When Naheed Kurji, CEO of Cyclica, inked a partnership with Italian pharmaceutical group Chiesi as a part of their $23M Series B, it represented a lot more than a commercialization strategy. It was the culmination of an all-too-unusual relationship between investor and CEO and it was proof that even when millions are on the line, honesty can win the day. — When I dialed up Naheed Kurji, CEO of Toronto-based Cyclica, an AI drug discovery company, and Ameya Phadke, head of technology partnerships at the Chiesi Group, it was to learn more about Cyclica’s recent $23M Series B, and the role the Italian pharmaceutical group played in it. I learned the…